Payment overview · 2025
General Payments
$104,406.05
215 reported records · 29 companies
Healthcare provider profile · identity verified
Brian J Brown, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SPARTANBURG, SC · NPI 1639494339
Verified facts
What the public records show
CMS Open Payments records show Brian J Brown, M.D. received $104,406.05 in general payments during 2025 across 215 reported records.
Shimadzu Precision Instruments, Inc. accounted for 50.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Shimadzu Precision Instruments, Inc. | Unresolved — no canonical attribution shown | $53,004.10 | 50.8% | 1 | 2025 |
| CMS Imaging, Inc. | Unresolved — no canonical attribution shown | $17,586.28 | 16.8% | 39 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $15,206.63 | 14.6% | 32 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $13,589.44 | 13.0% | 36 | 2025 |
| Infraredx, Inc. | Unresolved — no canonical attribution shown | $1,000.00 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $714.89 | 0.7% | 14 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $574.59 | 0.6% | 10 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $394.58 | 0.4% | 6 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $386.55 | 0.4% | 6 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $328.11 | 0.3% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $291.42 | 0.3% | 5 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $198.57 | 0.2% | 8 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $164.02 | 0.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$139.92 | 0.1% | 8 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $120.54 | 0.1% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $111.84 | 0.1% | 7 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $96.04 | 0.1% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $93.73 | 0.1% | 2 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $56.06 | 0.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.16 | 0.1% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.57 | 0.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.56 | 0.0% | 2 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $39.48 | 0.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.30 | 0.0% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $33.94 | 0.0% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $29.21 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.00 | 0.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.61 | 0.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.91 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $94,754.10 | 27 |
| Food and Beverage | $7,533.38 | 178 |
| Travel and Lodging | $1,928.58 | 8 |
| Gift | $189.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $15,206.63 | 32 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $13,632.88 | 35 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $13,632.88 | 35 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $574.59 | 10 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $424.87 | 4 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $394.58 | 6 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $394.58 | 6 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $340.43 | 5 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $195.66 | 8 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $144.44 | 1 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $135.78 | 4 | 2025 |
Source payment records
|
|||||
| Asahi Interventional Radiology Wires Normalized: asahi interventional radiology wires |
Device | ASAHI INTECC USA, INC. | $120.54 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $111.84 | 7 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $111.09 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $93.73 | 2 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $79.54 | 4 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $78.12 | 1 | 2025 |
Source payment records
|
|||||
| HemoSphere Normalized: hemosphere |
Device | Becton, Dickinson and Company | $61.72 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $61.37 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $60.94 | 2 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $58.44 | 2 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $56.06 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.16 | 3 | 2025 |
Source payment records
|
|||||
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $52.93 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $46.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $40.01 | 2 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $39.48 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| VitaWave Normalized: vitawave |
Device | Becton, Dickinson and Company | $34.32 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $31.62 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| OptiCross Normalized: opticross |
Device | Boston Scientific Corporation | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $12.01 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $10.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $3.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 268 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
268 | 75 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
268 | 75 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 586 | 204 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 106 |
| Furosemide | Furosemide | 294 | 117 |
| Eliquis | Apixaban | 268 | 75 |
| Carvedilol | Carvedilol | 248 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 92 |
| Spironolactone | Spironolactone | 144 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 59 |
| Lisinopril | Lisinopril | 129 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 37 |
| Xarelto | Rivaroxaban | 90 | 22 |
| Entresto | Sacubitril/Valsartan | 86 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 85 | 33 |
| Losartan Potassium | Losartan Potassium | 83 | 32 |
| Jardiance | Empagliflozin | 80 | 27 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 36 |
| Nitroglycerin | Nitroglycerin | 68 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 25 |
| Potassium Chloride | Potassium Chloride | 59 | 19 |
| Flecainide Acetate | Flecainide Acetate | 55 | 17 |
| Bumetanide | Bumetanide | 47 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 11 |
| Brilinta | Ticagrelor | 37 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 13 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $104,406.05 · 215 records | Shimadzu Precision Instruments, Inc. | ABRE, ALPHAVAC, ANGIOVAC, AVVIGO Guidance System, Asahi Interventional Radiology Wires, Barostim Neo System, BodyGuardian, CAMZYOS, CLOTTRIEVER BOLD CATHETER, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, ELIQUIS, ENDOCROSS Device, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, ESPRIT, FFRct, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GALLANT, General - Balloon Catheters, HAWKONE, HemoSphere, JOT DX, LEQVIO, LIMFLOW SYSTEM, LifeVest, Nimbl, ONPATTRO, OptiCross, PRODIGY CATHETER, PROTEGE RX, Paradise Ultrasound Renal Denervation System, REPATHA, SAPIEN 3 Ultra RESILIA, SYMPHONY CATHETER, Serrantor, Torus Stent Graft System, VERQUVO, VitaWave, WATCHMAN FLX, Wegovy, XIENCE SKYPOINT | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error